Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Total Non-Current Liabilities data on file, last reported at $57.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 42.27% year-over-year to $57.7 million; the trailing twelve-month figure through Dec 2025 stood at $57.7 million (up 42.27% YoY), and the FY2025 full-year result was $57.7 million, up 42.27% from the prior year.
• Total Non-Current Liabilities advanced to $57.7 million in Q4 2025, from $40.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.7 million in Q4 2025 to a low of $5.5 million in Q3 2021.
• A 5-year average of $25.2 million and a median of $26.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 411.57% in 2022 and decreased 21.49% in 2024, its largest moves.
• Tracing CADL's Total Non-Current Liabilities over 5 years: stood at $6.8 million in 2021, then surged by 312.19% to $28.1 million in 2022, then retreated by 1.98% to $27.5 million in 2023, then surged by 47.2% to $40.5 million in 2024, then soared by 42.27% to $57.7 million in 2025.
• Business Quant data shows CADL's Total Non-Current Liabilities at $57.7 million in Q4 2025, $40.5 million in Q4 2024, and $20.9 million in Q3 2024.